SSelectStock

SURAKSHASuraksha Diagnostic Limited

Healthcare · Diagnostics & Research · NSE · as of 2026-09-11 (delayed ~30 min in market hours)

Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity test. In addition, the company provides dental, physiotherapy, immunology & rheumatology, eye, fetal care, ENT, and speciality clinics, as well as home doctor visit services. The company was founded in 1992 and is based in Kolkata, India.

323.75
1.25%
72Strong

Mkt Cap
₹1,685 Cr
P/E
47.0
P/B
6.9
Div Yield
0.00%
52W High
₹349.00
52W Low
₹224.10

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)1,684.60
P/E46.99
P/B6.85
PEG1.22
ROE %13.10
ROCE %14.50
Debt / Equity0.54
EPS6.89
Revenue Growth %20.70
Profit Growth %38.90
Dividend Yield %0.00
Promoter Holding %61.97
FII Holding %22.47
DII Holding %
Beta0.49

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

BUYConviction 82%

Why buy

  • Revenue growth: 20.7% YoY
  • Profit growth: 38.9% YoY
  • Debt/Equity: 0.54
  • RSI: 55
  • Price vs EMA21: above
  • Price vs SMA50: above
  • Pullback to 21-EMA signal (setup quality 80%)

Bull case

  • Revenue growth: 20.7% YoY
  • Profit growth: 38.9% YoY
  • Debt/Equity: 0.54
  • RSI: 55

Bear case

  • Dividend yield: 0.00%
  • MACD: bearish
  • Volume: 0.4x 20-day average
  • Volume trend: 0.6x baseline

Key risks

  • Dividend yield: 0.00%
  • MACD: bearish

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹323.75
Stop Loss
₹292.89
risk 9.5%
Target 1 (1.5R)
₹370.04
+14.3%
Target 2 (3R)
₹416.33
+28.6%
Support (20d)
₹295.85
Resistance (52w)
₹349.00
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹30.86/share
ATR (volatility)
₹12.87
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹12.87). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental76
Technical65
Momentum79
Risk (safety)63

Peers — Healthcare

GKSL 1.23%
79
NEPHROPLUS 2.42%
74
KOVAI 1.41%
73
SAILIFE 0.38%
73
METROPOLIS 1.70%
73
VIJAYA 0.21%
72